Abstract
Objectives: To document the management of advanced prostate cancer including diagnosis, prognosis, treatment, and care, in real-world practice in Asia using the United in Fight against prOstate cancer (UFO) registry. Patients and Methods: We established a multi-national, longitudinal, observational registry of patients with prostate cancer presenting to participating tertiary care hospitals in eight Asian countries. A total of 3636 eligible patients with existing or newly diagnosed high-risk localised prostate cancer (HRL), non-metastatic biochemically recurrent prostate cancer (M0), or metastatic prostate cancer (M1), were consecutively enrolled and are being followed-up for 5 years. Patient history, demographic and disease characteristics, treatment and treatment decisions, were collected at first prostate cancer diagnosis and at enrolment. Patient-reported quality of life was prospectively assessed using the European Quality of Life-five Dimensions, five Levels (EQ-5D-5L) and Functional Assessment of Cancer Therapy for Prostate Cancer questionnaires. In the present study, we report the first interim analysis of 2063 patients enrolled from study start (15 September 2015) until 18 May 2017. Results: Of the 2063 enrolled patients, 357 (17%), 378 (19%), and 1328 (64%) had HRL, M0 or M1 prostate cancer, respectively. The mean age at first diagnosis was similar in each group, 56% of all patients had extracapsular extension of their tumour, 28% had regional lymph node metastasis, and 53% had distant metastases. At enrolment, 62% of patients had at least one co-morbidity (mainly cardiovascular disease or diabetes), 91.8% of M1 patients had an Eastern Cooperative Oncology Group performance score of <2 and the mean EQ-5D-5L visual analogue score was 74.6–79.6 across cohorts. Treatment of M1 patients was primarily with combined androgen blockade (58%) or androgen-deprivation therapy (either orchidectomy or luteinising hormone-releasing hormone analogues) (32%). Decisions to start therapy were mainly driven by treatment guidelines and disease progression. Decision to discontinue therapy was most often due to disease progression (hormonal drug therapy) or completion of therapy (chemotherapy). Conclusion: In the UFO registry of advanced prostate cancer in Asia, regional differences exist in prostate cancer treatment patterns that will be explored more deeply during the follow-up period; prospective follow-up is ongoing. The UFO registry will provide valuable descriptive data on current disease characteristics and treatment landscape amongst patients with prostate cancer in Asia.
| Original language | English |
|---|---|
| Pages (from-to) | 541-552 |
| Number of pages | 12 |
| Journal | BJU International |
| Volume | 125 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2020 Apr 1 |
Bibliographical note
Funding Information:Edmund Chiong reports receiving institutional grants from Janssen during the conduct of the study, and honoraria and conference support from Janssen outside the submitted work.
Funding Information:
All costs associated with development of this manuscript were funded by Janssen. The corresponding author had final responsibility for the decision to submit for publication. Operations support for data collection and data cleaning was provided by Angelia Sim (Global Trial Manager at Johnson & Johnson, Pte. Ltd.). Investigators and site coordinators from the following sites have graciously given their time and effort in entering and reviewing data for the benefit of this registry: Gao Xin, the 3rd Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China; Hu Zhiquan, Tongi Hospital, Tongi Medical College, Huazhong University, Wuhan, Hubei, China; Radheshyam Devanna Naik, Healthcare Global (HCG) Hospital, Bengaluru, Karnataka, India; Amlesh Seth, All India Institute of Medical Sciences, New Delhi, Delhi, India; Amit Joshi, Tata Memorial Hospital, Mumbai, Maharashtra, India; Gaku Arai, Dokkyo Medical University Koshigaya Hospital, Koshigaya, Saitama, Japan; Motohide Uemura, Osaka University Hospital, Suita, Osaka, Japan. Junya Furukawa, Kobe University Hospital, Kobe, Hyogo, Japan; Katsuyoshi Hashine NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; Ji Youl Lee, St. Mary?s Hospital, The Catholic University of Korea, Seoul, South Korea; Cheol Kwak, Seoul National University Hospital, Seoul, South Korea; Hyun Moo Lee, Samsung Medical Center, Seoul, South Korea; Yew Lam Chong, Tan Tock Seng Hospital, Singapore, Singapore; Apirak Santingamkun, King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Choosak Pripatananont, Songkhla Hospital, Songkhla, Thailand; Tong-Lin Wu, Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan. Writing assistance was provided by Joanne Wolter (independent writer on behalf of Janssen).
Publisher Copyright:
© 2019 The Authors BJU International Published by John Wiley & Sons Ltd on behalf of BJU International
All Science Journal Classification (ASJC) codes
- Urology
